First Time Loading...

Myriad Genetics Inc
NASDAQ:MYGN

Watchlist Manager
Myriad Genetics Inc Logo
Myriad Genetics Inc
NASDAQ:MYGN
Watchlist
Price: 19.32 USD 6.27%
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one MYGN stock under the Base Case scenario is 36.71 USD. Compared to the current market price of 19.32 USD, Myriad Genetics Inc is Undervalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MYGN Relative Value
Base Case
36.71 USD
Undervaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.2
P/S
P/S
Price to Sales
2.2
vs History
73
vs Industry
79
Median 3Y
2.7
Median 5Y
2.6
Industry
8.1
Forward
2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-14.5
Industry
26.2
Forward
803.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-15.2
Median 5Y
-10.3
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-10.8
Industry
21.3
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
46
vs Industry
42
Median 3Y
2.2
Median 5Y
2
Industry
2.5
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
71
vs Industry
69
Median 3Y
2.4
Median 5Y
2.4
Industry
7.3
Forward
1.8
More Details
3
EV/GP
EV/GP
Enterprise Value to Gross Profit
3
vs History
68
vs Industry
66
Median 3Y
3.5
Median 5Y
3.4
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-21.2
Median 5Y
-15.1
Industry
4.4
Forward
48.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-12.2
Industry
4.3
Forward
508
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-13.4
Median 5Y
-8.9
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-7
Industry
3.2
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
49
vs Industry
52
Median 3Y
1.7
Median 5Y
1.6
Industry
5
More Details

Multiples Across Competitors

MYGN Competitors Multiples
Myriad Genetics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Myriad Genetics Inc
NASDAQ:MYGN
1.7B USD 2.2 -6.3 -20.8 -11.4
US
Abbvie Inc
NYSE:ABBV
280.4B USD 5.2 58.2 12.7 19.3
US
Amgen Inc
NASDAQ:AMGN
146.3B USD 5.2 21.7 16.2 24.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 10.3 28.2 22.6 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.9B USD 7.5 24.8 16.4 18
AU
CSL Ltd
ASX:CSL
132.9B AUD 6.1 35.1 21.3 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
82.8B USD 3.1 14.6 8 10.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
42.6B USD 6.2 -9 -9.6 -8.2
US
Biogen Inc
NASDAQ:BIIB
31.6B USD 3.2 27.2 14.7 18.2
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47
EV/EBITDA Multiple
EBITDA Growth
US
Myriad Genetics Inc
NASDAQ:MYGN
Average EV/EBITDA: 17.5
Negative Multiple: -20.8 		N/A
US
Abbvie Inc
NYSE:ABBV
12.7
26%
US
Amgen Inc
NASDAQ:AMGN
16.2
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
50%
AU
CSL Ltd
ASX:CSL
21.3
54%
US
Gilead Sciences Inc
NASDAQ:GILD
8
18%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.6 N/A
US
Biogen Inc
NASDAQ:BIIB
14.7
67%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
27.9
83%

See Also

Summary
MYGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
MYGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MYGN stock valuation using valuation multiples.
Wall Street Estimates
MYGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MYGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.